More sops in the offing for India's generic pharma sector

24 January 2022

Generic medicines in India have received a new impetus with both Prime Minister Narendra Modi and Venkaiah Naidu, Vice President of India, calling on the domestic pharmaceutical industry to work towards making India an international capital of generic drugs. With the leaders hinting at a policy push towards further consolidating India’s domestic pharmaceutical industry, more grants in the form of additional PLI schemes appear to be in the offing, reports The Pharma Letter’s India correspondent.

Advocating the usage of generic medicines, both the stalwarts said, on separate occasions, that patent expiry of branded drugs is set to open up novel avenues for generic drug players.

The Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the USA and 25% of all medicine in the UK, according to government data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK